C12N 2760/18832
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2760/18832 (Use of virus as therapeutic agent, other than vaccine) appears on 9 US grants and 15 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 15
- Assignees
- 8
- Inventors
- 36
- Latest grant
- 26 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 2 |
| 2006 | 0 | 1 |
| 2007 | 1 | 1 |
| 2008 | 0 | 2 |
| 2009 | 2 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 1 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
By publication year.
Recent patents
- Composition comprising NC886 for improving oncolytic virus activity or production26 Aug 2025US 12,398,376 B2National Cancer Center
- Methods for making and using modified oocytes16 Mar 2021US 10,947,562 B2New York Stem Cell Foundation, Inc.
- Methods for making and using modified oocytes16 Jul 2019US 10,351,876 B2New York Stem Cell Foundation, Inc.
- Genetically modified paramyxovirus for treatment of tumor diseases21 Nov 2017US 9,821,016 B2Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum
- Methods for making and using modified oocytes6 Sep 2016US 9,434,960 B2New York Stem Cell Foundation, Inc.
- Retroviral vectors14 Mar 2024US 2024/0082327 A1
- Medicament for treating cancer, immunostimulant, and method for screening for anti-cancer substance12 Oct 2023US 2023/0321165 A1Osaka University
- Composition comprising nc886 for improving oncolytic virus activity or production27 Jan 2022US 2022/0025338 A1National Cancer Center
- Methods for making and using modified oocytes1 Jul 2021US 2021/0198697 A1New York Stem Cell Foundation, Inc.
- Methods for making and using modified oocytes7 Nov 2019US 2019/0338313 A1New York Stem Cell Foundation, Inc.
Most cited
By later US patents
- Anticancer agent containing dendritic cell having RNA virus transferred thereinto11US 8,889,118 B2DNA VEC Research Inc. · 2014
- Genetically modified paramyxovirus for treatment of tumor diseases2US 9,821,016 B2Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum · 2017
- Method for introducing a biological molecule using a viral envelope and heparin and system therefore1US 7,504,098 B2AnGes MG, Inc. · 2009